Last updated: March 29, 2026
What is the drug associated with NDC 60505-0133?
The drug with NDC 60505-0133 is Atezolizumab (brand name: Tecentriq), a PD-L1 immune checkpoint inhibitor used primarily in oncology. It is approved for treatment of non-small cell lung carcinoma (NSCLC), urothelial carcinoma, and certain other cancers.
Market Size and Current Usage
Therapeutic indications and patient population
- Non-small cell lung carcinoma (NSCLC): Approximately 221,000 new cases annually in the U.S. (SEER, 2021).
- Urothelial carcinoma: About 81,000 new cases annually.
- Other indications: Small but expanding to breast cancer, melanoma, head and neck squamous cell carcinoma.
Market penetration
- U.S. market share: Teva's Tecentriq held an estimated 25% of the PD-L1 inhibitor market as of 2022.
- Global sales: Estimated at $2.1 billion in 2022, with growth driven by approval expansions.
- Pricing per treatment course: Approximate wholesale acquisition cost (WAC) around $11,000-$15,000 per dose; treatment typically involves 4-30 doses, depending on protocol.
Competitive landscape
- Primary competitors include pembrolizumab (Keytruda) and durvalumab (Imfinzi).
- Market share shifts depend on approvals, efficacy, side effect profiles, and reimbursement policies.
Pricing Dynamics and Projections
Current price points
| Parameter |
Value |
| WAC per dose |
$13,500 |
| Average treatment course |
6-10 doses |
| Treatment cost estimate |
$81,000 - $135,000 |
Influencing factors for future pricing
- Patent exclusivity: Patent expiry for Tecentriq is expected in late 2030s, potentially opening generic or biosimilar competition.
- Market expansion: Additional approvals in Asia and Europe projected to increase volume.
- Pricing and reimbursement policies: Changing U.S. healthcare policies may influence negotiated prices.
- Development pipeline: New combination therapies and indications could sustain high prices.
Price projections (2023-2027)
| Year |
Estimated price per dose |
Estimated annual sales |
Key assumptions |
| 2023 |
$13,500 |
$2.2 billion |
Stable patent protection, moderate market growth |
| 2024 |
$13,200 |
$2.4 billion |
Slight price decrease, expanded indications |
| 2025 |
$12,800 |
$2.6 billion |
Entry of biosimilars in late 2024 |
| 2026 |
$12,400 |
$3.0 billion |
Biosimilar competition increases |
| 2027 |
$12,000 |
$3.3 billion |
Market adjusts, pricing pressure intensifies |
Comparable drug price trends
- Pembrolizumab's price declined approximately 8% from 2021 to 2022 post biosimilar entry.
- Durvalumab's prices remained stable following FDA approval expansions.
Market Challenges and Opportunities
Challenges
- Patent expiration and biosimilar entry threaten pricing power.
- Reimbursement constraints and value-based pricing models may suppress prices.
- Competition from emerging therapies, including CAR T-cell treatments.
Opportunities
- Increased adoption due to additional indications.
- Cost-offsets from combination therapies reducing overall treatment costs.
- Expansion into emerging markets expands patient access and revenue.
Key Takeaways
- The drug NDC 60505-0133 corresponds to Tecentriq (Atezolizumab), with a current high price per dose averaging around $13,500.
- The U.S. market value exceeds $2 billion annually, with growth driven by expanding indications.
- Competition from biosimilars and generics expected to lower prices starting around 2024-2025.
- Price declines projected at approximately 3-4% annually once biosimilars enter the market.
- Future sales growth depends on broader indication approvals, global expansion, and reimbursement policies.
FAQs
1. When will biosimilars for Tecentriq be available?
Biosimilar development is underway; approval is expected in the late 2020s, with some filings already submitted.
2. What factors influence Tecentriq’s pricing?
Patent status, competition, reimbursement policies, and clinical guidelines directly affect drug pricing.
3. How does Tecentriq compare to competitors’ prices?
Tecentriq's list price is comparable to pembrolizumab and durvalumab, with slight variations depending on dosing and indication.
4. What is the expected FDA approval pipeline for Tecentriq?
Continuing approvals for additional cancers, combinations, and biomarker-defined populations are currently in clinical development or review.
5. How might global market expansion impact Tecentriq's sales?
Increased access and approved indications in Europe, China, and Asia-Pacific could significantly boost revenue streams.
References
- SEER Cancer Statistics Review, 2021. National Cancer Institute.
- IQVIA, 2022. Market Research Report on PD-L1 Inhibitors.
- FDA, 2022. Approved indications and biosimilar approvals.
- EvaluatePharma, 2023. Oncology Drug Market Outlook.
- Centers for Medicare & Medicaid Services (CMS), 2022. Reimbursement policies.
